Select a year:

4Moving Biotech announces the equity investment of the Arthritis Foundation to support the clinical development of its disease-modifying osteoarthritis drug candidate

4Moving Biotech, a spin-off of 4P-Pharma focusing on the development of 4P004, a first-in-class Disease Modifying OsteoArthritis Drug (DMOAD) announces the equity investment of the Arthritis Foundation to support the clinical development of its disease-modifying osteoarthritis drug candidate. “We are very pleased with the commitment of the Foundation Arthritis. Patients have always been the core of our&hellip

Read More

4P-Pharma will attend the 10th DDIP, November 28th-29th 2019 – Barcelona, Spain

We’re glad to announce that Céline Martin, 4P-Pharma’s R&D Manager will speak during  the 10th Drug Discovery Innovation Programme (10th DDIP) organized by the World BI, November 28th-29th 2019, at Barcelona, Spain: “Pharmaceutical Development Through A Rapid Value Creation Business Model”. To learn more about 4P-Pharma, our pipeline and our partnerships, please feel free to&hellip

Read More

4P-Pharma an actor in ADHD pipeline drug development

4P-Pharma is a recognized actor in the ADHD pipeline drug development. Stimulant abuse and addiction is a major global health problem and prescription drugs are indeed more and more abused, in virtue of their “rewarding” psychotropic effects.  ADHD medications abuse increased by 4 fold, and led to a 400% increased in emergency room visits from&hellip

Read More